UCB cuts $1.15bn deal to buy epilepsy biotech Neurona
UCB has dipped its toe into the M&A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.
Changing Faces: Digital and supplier, March 2026
Digital health companies, clinical trial technology providers, and life sciences suppliers continued to invest in senior leadership in March.
Trump signs order to hasten psychedelic medicine access
Donald Trump has signed an executive order directing the FDA to reduce regulatory hurdles that stand in the way of bringing psychedelics to patients.
The conflict in the Middle East is exposing dangerous prepar...
If the conflict persists, the risk of widespread medicine shortages becomes increasingly real.
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
Axtria Acquires Conexus Solutions, Uniting Agentic AI and CR...
Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced the acquisition of Conexus Solutions
PHARMAP 2026: From Vendors to Strategic Partners
Strategic Partnerships at PHARMAP 2026 – Big Pharma’s Shift Toward CDMOs and CMOs
WOMA 2026: Steering the Future of Pharma Strategy
The WOMA Forum is not merely a conference. It's a convergence point for decision-makers
6th mRNA‑Based Therapeutics Summit
Advancing mRNA's Therapeutic Potential to Combat All Diseases
Agentic AI is Ready. Most Pharma Organizations Are Not
Axtria Ignite 2026 returns June 10–11 in Princeton, New Jersey